Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. (Q39590044)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Elisabetta Falcieri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Andrea Pession

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

James A. McCubrey

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

F Ricci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

P Tazzari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

G Tabellini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

M Battistelli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

F Chiarini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Bortul

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

F Melchionda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

P Pagliaro

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

A M Martelli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

18 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

781-791

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.20

22 January 2020

exact match

0 references

cites work

Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeting the translational machinery as a novel treatment strategy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Isolation of hyperactive mutants of mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.20

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331075%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference